Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 15/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 0.51 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12150845 | 0.92 | ADK (0.56) | ADKADORA2APRMT5WDR77METTL3 | |
| SCHEMBL6841559 | 0.92 | ADK (0.56) | ADKADORA2APRMT5WDR77METTL3 | |
| SCHEMBL12154683 | 0.92 | ADK (0.56) | ADKADORA2APRMT5WDR77METTL3 | |
| SCHEMBL731889 | 0.92 | ADK (0.56) | ADKADORA2APRMT5WDR77METTL3 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL6422519 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 | |
| SCHEMBL733393 | 0.88 | ADK (0.53) | ADKADORA2APRMT5WDR77METTL3 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL733423 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL12149452 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 | |
| SCHEMBL475133 | 0.88 | ADK (0.53) | ADKADORA2APRMT5WDR77METTL3 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL14628545 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943538-B1 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADK 239/4885ADORA2A 416/4885PRMT5 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.